Targets › FGA
2 programs from 2 companies in 2 trials: 2 Phase 3; Hematology, Other; next expected readout Dec 2026.
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. (UniProt, P02671)
Open in Phaseline: the race on FGA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Corza Medical | Fibrinogen, Human Fibrinogen exogenous protein | FGA, FGB, FGG | Phase 3 | Hemorrhage | Dec 2026 |
| CSL Behring | CSL511 Fibrinogen concentrate (human) Fibrinogen (clotting factor I) replacement | FGA | Phase 3 | Acquired Fibrinogen Deficiency | Jun 2027 |
Acquired Fibrinogen Deficiency (1) Hemorrhage (1)
protein or peptide (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.